All In Biotech

Drug Trial Radar · NCT05205070

A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in the Treatment of Subjects With Alopecia Areata

Last checked: Nov 19, 2026Latest source record: May 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

45

Planned (sponsor's estimate)

Start

Dec 22, 2021

Primary completion

Jan 19, 2023

Study completion Mar 19, 2023

Sponsor

Lead sponsor
AnaptysBio, Inc.Industry
Sponsor type
Industry
First posted
Jan 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Efficacy and safety of rosnilimab (ANB030) in subjects with moderate-to-severe Alopecia Areata

Conditions

  • Alopecia Areata

Interventions

  • RosnilimabBiological

    humanized monoclonal antibody

  • PlaceboBiological

    Placebo solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Severity of Alopecia Tool (SALT) score at Week 24Time frame: Week 24

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • 10-105

    Birmingham, Alabama · Recruiting

  • Site10-103

    Encinitas, California · Recruiting

  • Site 10-113

    Northridge, California · Recruiting

  • Site 10-115

    Chicago, Illinois · Recruiting

  • 10-104

    Indianapolis, Indiana · Recruiting

  • Site 10-109

    Plainfield, Indiana · Recruiting

  • Site 10-116

    Louisville, Kentucky · Recruiting

  • Site 10-117

    Clarkston, Michigan · Recruiting

  • Site 10-111

    New York, New York · Recruiting

  • Site 10-101

    Charlotte, North Carolina · Recruiting

  • Site 10-102

    Bexley, Ohio · Recruiting

  • Site 10-106

    Tulsa, Oklahoma · Recruiting

  • 10-107

    Upper Saint Clair, Pennsylvania · Recruiting

  • 10-110

    Houston, Texas · Recruiting

  • Site 10-108

    San Antonio, Texas · Recruiting

  • Site 10-114

    Kenosha, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.